Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 728

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 1A
Chunk 728
---
 sale of oncology business200,000 — — Payments associated with license agreement— (17,500)— Purchases of property and equipment(1,685)(999)(4,881)Proceeds from sale of equipment40 1,325 964 Net cash provided by investing activities363,441 239,575 243,261 Financing activitiesPayments on financing lease obligations— — (331)Net proceeds from stock option exercises and employee stock purchase plan14,442 5,433 2,681 Net cash provided by financing activities14,442 5,433 2,350 Net change in cash and cash equivalents(11,958)(51,054)(63,867)Cash and cash equivalents at beginning of the period88,205 139,259 203,126 Cash and cash equivalents at end of the period$76,247 $88,205 $139,259 Supplemental disclosure of non-cash investing and financing transactions:Additions to property and equipment in accounts payable and accrued expenses$317 $55 $158 Net cash taxes paid$43,150 $1,569 $— 

See accompanying Notes to Consolidated Financial Statements.

F-8

Agios Pharmaceuticals, Inc.

Notes to Consolidated Financial Statements

Note 1. Nature of Business

References to AgiosThroughout this Annual Report on Form 10-K, “the Company,” “Agios,” “we,” “us,” and “our,” and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and “our board of directors” refers to the board of directors of Agios Pharmaceuticals, Inc. OverviewWe are a biopharmaceutical company committed to transforming patients’ lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning of nearly every system in the body. Building on this expertise, these learnings can be rapidly applied to our clinical trials with the goal of developing medicines that can have a significant impact for patients. We accelerate the impact of our portfolio by cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for rare diseases. We are located in Cambridge, Massachusetts.The lead product candidate in